Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P43146 (
tumour suppressor
)
5,935
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A major target of the HPV E6 oncoprotein is the human Discs Large (hDlg)
tumour suppressor
, although how this interaction contributes to HPV-induced malignancy is still unclear. Using a proteomic approach we show that a strong interacting partner of hDlg is the RhoG-specific guanine nucleotide exchange factor
SGEF
. The interaction between hDlg1 and
SGEF
involves both PDZ and SH3 domain recognition, and directly contributes to the regulation of
SGEF
's cellular localization and activity. Consistent with this, hDlg is a strong enhancer of RhoG activity, which occurs in an
SGEF
-dependent manner. We also show that HPV-18 E6 can interact indirectly with
SGEF
in a manner that is dependent upon the presence of hDlg and PDZ binding capacity. In HPV transformed cells, E6 maintains a high level of RhoG activity, and this is dependent upon the presence of hDlg and
SGEF
, which are found in complex with E6. Furthermore, we show that E6, hDlg and
SGEF
each directly contributes to the invasive capacity of HPV-16 and HPV-18 transformed tumour cells. These studies demonstrate that hDlg has a distinct oncogenic function in the context of HPV induced malignancy, one of the outcomes of which is increased RhoG activity and increased invasive capacity.
...
PMID:The invasive capacity of HPV transformed cells requires the hDlg-dependent enhancement of SGEF/RhoG activity. 2238 78